An interventional study of Optical coherence tomography (OCT) and Optical coherence tomograpohy angiography (OCTA) in Optical Coherence Tomography, Optical Coherence Tomography Angiography and Retinal Thickening, sponsored by Centre Hospitalier Universitaire, Amiens. Completed at 1 site in France. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-12-08.
Sponsored by Centre Hospitalier Universitaire, Amiens · Not applicable, Interventional, and Diagnostic
Alzheimer disease is hard, long and expensive to diagnose. In order to help the clinician, a new biomarker in Alzheimer disease seems to be very useful. The retina, as a window of the brain, could offer a new way to diagnose this common disease. Indeed, a retinal atrophy could especially appear in Alzheimer disease. Besides, many aspects about retinal alteration, visual function and their link with the disease deserve to be more explored. So as to fill these gaps, a new study about retinal specificity in Alzheimer disease appears to be relevant.
3,678 studies on the registry are indexed under Alzheimer Disease; 872 are open to participants now.
This study's enrollment of 55 is below the median of 70 across 2,808 interventional studies indexed under Alzheimer Disease.
Browse Alzheimer Disease studies →Centre Hospitalier Universitaire, Amiens is the lead sponsor of 576 studies on the registry; 178 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Diagnostic Test: Optical coherence tomography (OCT) · Diagnostic Test: Optical coherence tomograpohy angiography (OCTA)
Diagnostic Test: Optical coherence tomography (OCT) · Diagnostic Test: Optical coherence tomograpohy angiography (OCTA)
Diagnostic Test: Optical coherence tomography (OCT) · Diagnostic Test: Optical coherence tomograpohy angiography (OCTA)
to make a complete ophthalmological and neurological examination, an OCT to AD and to compare their results with LD and controls subjects
to make a complete ophthalmological and neurological examination, an OCT and OCTA, to AD and to compare their results with LD and controls subjects
Variation of retinal nerve fibres layer (RNFL) thickness in AD patient compared to healthy and LMD patients
Thickness of retinal nerve fibres layer (RNFL), ganglion cell layer (CGL), intern plexiform layer (IPL) within the macular zone of patients suffering from AD.
Time frame: one day
Variation of ganglion cell layer (CGL) thickness in AD patient compared to healthy and LMD patients
Thickness of retinal nerve fibres layer (RNFL), ganglion cell layer (CGL), intern plexiform layer (IPL) within the macular zone of patients suffering from AD.
Time frame: one day
Variation of intern plexiform layer (IPL) thickness in AD patient compared to healthy and LMD patients
Thickness of retinal nerve fibres layer (RNFL), ganglion cell layer (CGL), intern plexiform layer (IPL) within the macular zone of patients suffering from AD.
Time frame: one day
Plan to share: No
No publications or documents are linked to this record.
This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Centre Hospitalier Universitaire, Amiens